•
Sep 30, 2024
Enfusion Q3 2024 Earnings Report
Revenue growth and adjusted EBITDA margins expansion were achieved.
Key Takeaways
Enfusion reported a solid quarter with a 15.4% year-over-year revenue growth, driven by product initiatives and expansion outside of global money centers. The company narrowed its full year revenue guidance to $202M-$205M and Adjusted EBITDA guidance to $41M-$45M.
Product initiatives such as Portfolio Workbench have expanded serviceable addressable market.
The Americas is on track for the best launch market since 2021.
Continued to expand footprint outside the global money centers.
Company is on track to becoming a “Rule of 40” Company over the 2025-2027 time period.
Enfusion
Enfusion
Enfusion Revenue by Segment
Forward Guidance
Enfusion narrowed its full year revenue guidance to $202M-$205M and Adjusted EBITDA guidance to $41M-$45M.
Revenue & Expenses
Visualization of income flow from segment revenue to net income